Deactivation of the sympathetic nervous system in patients with chronic congestive heart failure

Current Cardiology Reports

Volumn 2, Issue 3, 2000, Pages 225-232

  Gilbert, Edward M ^a   Port, J David ^b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; CARVEDILOL; METOPROLOL; PROPANOLAMINE DERIVATIVE;

ADRENERGIC SYSTEM; CONGESTIVE HEART FAILURE; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HUMAN; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; HEART FAILURE, CONGESTIVE; HUMANS; METOPROLOL; PROPANOLAMINES; RECEPTORS, ADRENERGIC; SIGNAL TRANSDUCTION; SYMPATHETIC NERVOUS SYSTEM; VENTRICULAR FUNCTION, LEFT;

EID: 0034186435     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0073-7     Document Type: Article

References (57)

1. Bristow MR, Ginsburg R, Umans V, et al. : Beta 1-and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. Circ Res 1986, 59:297-309.
2. Bristow MR, Hershberger RE, Port JD, et al. : Beta 1-and beta 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989, 35:295-303.
3. Cohn JN, Levine TB, Olivari MT: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311:819-823.
4. Port JD, Malbon CC: Integration of transmembrane signaling. Cross-talk among G-protein-linked receptors and other signal transduction pathways. Trends Cardiovasc Med 1993, 3:85-92.
5. Frielle T, Collins S, Daniel K, et al. : Cloning of the cDNA for the human b1-adrenergic receptor. Proc Natl Acad Sci U S A 1987, 84:7920-7924.
6. Kobilka B, Dixon R, Frielle T, et al. : cDNA for the human b2-adrenergic receptor: a protein with multiple membranespanning domains and encoded by a gene whose chromosomal location is shared with that of the receptor for platelet-derived growth factor. Proc Natl Acad Sci U S A 1988, 84:46-50.
7. Emorine LJ, Marullo S, Briend-Sutren MM, et al. : Molecular characterization of the human beta 3-adrenergic receptor. Science 1989, 245:1118-1121.
8. Gauthier C, Tavernier G, Charpentier F, et al. : Functional beta3-adrenoceptor in the human heart [see comments]. J Clin Invest 1996, 98:556-562.
9. Bristow M, Anderson F, Port J, et al. : Differences in b-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991, 84:1024-1039.
10. Bristow MR, Hershberger RE, Port JD, et al. : Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990, 82:I12-I25.
11. White M, Roden R, Minobe W, et al. : Age-related changes in b-adrenergic neuroeffector systems in the human heart. Circulation 1994, 90:1225-1238.
12. Drazner MH, Peppel KC, Dyer S, et al. : Potentiation of b-adrenergic signaling by adenoviral-mediated gene transfer in adult rabbit ventricular myocytes. J Clin Invest 1997, 99:288-296.
13. Ungerer M, Bohm M, Elce J, et al. : Altered expression of b-adrenergic receptor kinase and b1-adrenergic receptors in the failing human heart. Circulation 1993, 87:454-463.
14. Daaka Y, Luttrell LM, Lefkowitz RJ: Switching of the coupling of the b2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997, 390:88-91.
15. Levy FO, Zhu X, Kaumann AJ, Birnbaumer L: Efficacy of b1-adrenergic receptors is lower that that of b2-adrenergic receptors. Proc Natl Acad Sci U S A 1993, 90:10798-10802.
16. Colledge M, Scott JD: AKAPs: from structure to function. Trends Cell Biol 1999, 9:216-221.
17. Zhou YY, Cheng H, Bogdanov KY, et al. : Localized cAMPdependent signaling mediates beta 2-adrenergic modulation of cardiac excitation-contraction coupling. Am J Physiol 1997, 273:H1611-H1618.
18. Bogoyevitch MA, Andersson MB, Gillespie-Brown J, et al. : Adrenergic receptor stimulation of the mitogen-activated protein kinase cascade and cardiac hypertrophy. Biochem J 1996, 314:115-121.
19. Luttrell LM, Ferguson SS, Daaka Y, et al. : Beta-arrestindependent formation of beta2 adrenergic receptor-Src protein kinase complexes [see comments]. Science 1999, 283:655-661.
20. Williams NG, Zhong H, Minneman KP: Differential coupling of alpha1-, alpha2-, and beta-adrenergic receptors to mitogen-activated protein kinase pathways and differentiation in transfected PC12 cells. J Biol Chem 1998, 273:24624-24632.
21. Steinberg SF: The molecular basis for distinct beta-adrenergic receptor subtype actions in cardiomyocytes. Circ Res 1999, 85:1101-1111.
22. Communal C, Singh K, Sawyer DB, Colucci WS: Opposing effects of beta(1)-and beta(2)-adrenergic receptors on cardiac myocyte apoptosis : role of a pertussis toxin-sensitive G protein. Circulation 1999, 100:2210-2212.
23. Milano CA, Allen LF, Rockman HA, et al. : Enhances myocardial function in transgenic mice overexpressing the b2-adrenergic receptor. Science 1994, 264:582-586.
24. Koch W, Rockman H, Samama P, et al. : Cardiac function in mice overexpressing the b-adrenergic receptor kinase or a bARK inhibitor. Science 1995, 268:1350-1353.
25. Bisognano J, Pende A, Tremmel KD, et al. : Preliminary characterization of a transgenic mouse overexpressing the human b1-adrenergic receptor. J Invest Med 1997, 45:210A.
26. Bisognano J, Weinberger HD, Bohlmeyer TJ, et al. : Myocardial-directed overexpression of the human b1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 2000, in press.
27. Engelhardt S, Hein L, Wiesmann F, Lohse MJ: Progressive hypertrophy and heart failure in beta1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 1999, 96:7059-7064.
28. Iwase M, Uechi M, Vatner DE, et al. : Cardiomyopathy induced by cardiac Gs alpha overexpression. Am J Physiol 1997, 272:H585-H589.
29. Asai K, Yang GP, Geng YJ, et al. : Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. J Clin Invest 1999, 104:551-558.
30. Joseph J, Gilbert EM: The sympathetic nervous system in chronic heart failure. Prog Cardiovasc Dis 1998, 41:9-16.
31. Fowler MB, Laser JA, Hopkins GL, et al. : Assessment of the beta-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986, 74:1290-1302.
32. White M, Yanowitz F, Gilbert EM, et al. : Role of beta-adrenergic receptor down-regulation in the peak exercise response of patients with heart failure due to idiopathic dilated cardiomyopathy. Am J Cardiol 1995, 76:1271-1276.
33. Mann D, Kent R, Parsons B, Cooper IV G: Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation 1992, 85:790-804.
34. Communal C, Singh K, Pimental DR, Colucci WS: The b-adrenergic pathway mediates norepinephrine-stimulated apoptosis in vitro in adult rat cardiac myocytes. Circulation 1997, 96:I-117.
35. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 1999, 341:577-585.
36. Lowes BD, Chidiac P, Olsen S, et al. : Clinical relevance of inverse agonism and guanine nucleotide modulatable binding properties of b-adrenergic receptor blocking agents. Circulation 1994, 90:I-543.
37. Bristow MR, Larrabee P, Minobe W, et al. : Receptor pharmacology of carvedilol in the human heart. J Cardiovasc Pharmacol 1992, 19(Suppl 1):S68-S80.
38. Feuerstein G, Shusterman NH, Ruffulo RR: Carvedilol update IV: prevention of exidative stress, cardiac remodeling and progression of heart failure. Drugs Today 1997, 33:453-457.
39. Dandona P, Karne R, Ghanim H, et al. : Carvedilol inhibits reactive oxygen species generation by leukocytes and oxidative damage to amino acids. Circulation 2000, 101:122-124.
40. Talwar KK, Bhargava B, Upasani PT, et al. : Hemodynamic predictors of early intolerance and long-term effects of propranolol in dilated cardiomyopathy. J Card Fail 1996, 2:273-277.
41. The Xamoterol in Severe Heart Failure Study Group: Xamoterol in severe heart failure. Published erratum appears in Lancet 1990, 336(8716):698 [see comments]. Lancet 1990, 336:1-6.
42. Eichhorn EJ, Heesch CM, Barnett JH, et al. : Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994, 24:1310-1320.
43. Lowes BD, Gill EA, Abraham WT, et al. : Effects of carvedilol on left ventricular mass, chamber geometry, and mitral regurgitation in chronic heart failure. Am J Cardiol 1999, 83:1201-1205.
44. Olsen SL, Gilbert EM, Renlund DG, et al. : Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study [see comments]. J Am Coll Cardiol 1995, 25:1225-1231.
45. Hall SA, Cigarroa CG, Marcoux L, et al. : Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with betaadrenergic blockade. J Am Coll Cardiol 1995, 25:1154-1161.
46. Bristow MR, Gilbert EM, Abraham WT, et al. : Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators [see comments]. Circulation 1996, 94:2807-2816.
47. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial [see comments]. Lancet 1999, 353:9-13.
48. Packer M, Bristow MR, Cohn JN, et al. : The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group [see comments]. N Engl J Med 1996, 334:1349-1355.
49. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) [see comments]. Lancet 1999, 353:2001-2007.
50. Gilbert EM, Abraham WT, Olsen S, et al. : Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart. Circulation 1996, 94:2817-2825.
51. The BEST Steering Committee:Design of the b-blocker evaluation survival trial (BEST). Am J Cardiol 1995, 75:1220-1223.
52. Di Lenarda A, Sabbadini G, Salvatore L, et al. : Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group. J Am Coll Cardiol 1999, 33:1926-1934.
53. Kukin ML, Kalman J, Charney RH, et al. : Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999, 99:2645-2651.
54. Sanderson JE, Chan SK, Yip G, et al. : Beta-blockade in heart failure: a comparison of carvedilol with metoprolol. J Am Coll Cardiol 1999, 34:1522-1528.
55. Metra M, Nodari S, D'Aloia A, et al. : Effects of chronic betablockade on the hemodynamics and functional capacity of patients with heart failure: a randomized comparison between metoprolol and carvedilol [abstract]). Eur Heart J 1998, 19:P1720.
56. Bohler S, Saubadu S, Scheldwaert R, Figulla HR: Betaxolol versus carvedilol in chronic heart failure (BETACAR study). Rationale and design. Arzneimittelforschung 1999, 49:311-317.
57. Poole-Wilson PH, Remme WJ: COMET: a multicenter randomized double-blind study to compare the effect of carvedilol and metoprolol in mortality and morbidity in patients with moderate or severe congestive heart failure (NYHA II-IV) [abstract]. Cardiovasc Drug Ther 1999 13:24.